BiotechTube
SEQENS

SEQENS

Helsinki, Finland· Est.
seqens.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

SEQENS is a global, revenue-generating CDMO and specialty ingredients company with a strong industrial footprint across Europe, North America, and Asia. Its core business model is providing services and products across pharmaceuticals (including generics and custom APIs), personal care, and industrial specialties, supported by a comprehensive R&D platform. The company is privately held, reports over €1 billion in revenue, and employs approximately 2,700 people, positioning it as a significant mid-tier player in the outsourced pharmaceutical and fine chemicals market. Its strategy integrates a commitment to operational excellence and corporate social responsibility.

Small MoleculesDrug Delivery

Technology Platform

Integrated CDMO platform with multidisciplinary R&D (organic, inorganic, physical chemistry, process engineering, polymers) for small molecule and specialty ingredient development & manufacturing. Includes cell & gene therapy bioproduction via CELLforCURE subsidiary.

Opportunities

The growing trend of pharmaceutical outsourcing provides a steady stream of demand for its CDMO services.
The global shift towards sustainable and biobased ingredients in personal care and industrial applications opens new markets for its specialty chemical innovations.
Expansion into high-value cell and gene therapy manufacturing through its CELLforCURE facility taps into a rapidly growing advanced therapeutics sector.

Risk Factors

Operational risks include potential environmental, health, and safety incidents across its 16 global production sites.
The company faces intense competition in the CDMO and specialty chemicals markets, which could pressure margins.
Regulatory compliance risks are significant, as failures in GMP or other standards could lead to plant shutdowns and loss of revenue.

Competitive Landscape

SEQENS competes in a fragmented but competitive global market against large, diversified CDMOs like Lonza, Catalent, and Siegfried, as well as numerous regional and niche players. In specialty ingredients, it faces competition from major chemical companies and dedicated personal care ingredient suppliers. Its differentiation is based on its integrated 'lab to plant' model, broad geographic footprint, and stated commitment to sustainable chemistry.

More companies in Small Molecule Drugs →More companies in Finland →